Cormedixの空売り状況は、投資家がCormedixの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cormedix (NASDAQ:CRMD) 株価情報, 空売り情報

CORMEDIX INC

Cormedix

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Cormedix Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and raises the price target from $15 to $20.

Needham Maintains Buy on Cormedix, Raises Price Target to $20

CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares are hitting new 52-week highs on Monday after the company raised its sales guidance <a href="https://www.benzinga.com/pressreleases/25/06/g46048778/cormedix-inc-announces-customer-implementation">for the second quarter</a>.
What Happened: CorMedix said one of its Large Dialysis Organization (LDO) customers has started ordering with planned implementation in the second half of 2025.
The company said that implementation of its DefenCath catheter lock solution will initially target at least 50% more patients than previously planned with opportunity for even further expansion.
As a result, CorMedix made adjustments to its agreement with the customer and now expects a modest revenue increase in June with continued growth anticipated in the second half of the year. The company updated its second-quarter net sales guidance from $31 million to a range of $35 million to $40 million to reflect the expected increased use of product by the customer.
&#8220;Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections,&#8221; said Joseph Todisco, CEO of CorMedix.
D. Boral Capital analyst Jason Kolbert maintained CorMedix with a Buy rating on Monday and reiterated a price target of&nbsp;$15.
<h3 class="wp-block-heading">How To Buy CRMD Stock</h3>
By now you're likely curious about how to participate in the market for Cormedix &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
CRMD Price Action: <a href="http://benzinga.com/quote/CRMD">CorMedix shares</a> were up 23% at $16.74 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. CorMedix has traded as low as $3.61 over the past year. The stock is up approximately 111% on a year-to-date basis.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/46051518/this-ventas-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Ventas Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Monday: What&#8217;s Happening?</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

Movers

CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session amid the Robotaxi <a href="https://www.benzinga.com/markets/tech/25/06/46051889/teslas-4-20-robotaxi-disruption-waymo-should-be-worried">launch in Austin, TX</a>.
Tesla has officially rolled out its much-awaited Robotaxi in Austin, Texas, with a limited number of Model Y Robotaxis in the South Congress neighborhood.
&#8220;Our approach to autonomy also enables scalability: Tesla self-driving can be deployed anywhere it's approved,&#8221; the company said in a post on social media platform X on Sunday after the Robotaxi launch.
Tesla shares jumped 9.3% to $352.11 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>) shares jumped 49.5% to $26.36 after the company announced it will be acquired by C&amp;S Wholesale Grocers.</li>
<li>Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) gained 36.3% to $1.43 after the company announced a strategic sale of SomaLogic to Illumina.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) rose 25.6% to $17.10 after the company raised its second-quarter net sales guidance.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) gained 20.2% to $17.05.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) rose 19% to $26.47.</li>
<li>Epsium Enterprise Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) gained 16.5% to $26.62.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) rose 14.8% to $275.90 after the company announced a partnership with Fiserv to use its stablecoin platform with Fiserv&#8217;s digital banking and payment capabilities.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 13% to $2.9479 after announcing positive six-month clinical results from Type 1 diabetes study of Islet Cell Transplantation without Immunosuppression.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) rose 11.8% to $24.11.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) gained 10% to $44.39 after the company topline results from the STELLAR-303 phase 3 pivotal trial. Also, JMP Securities raised its price target on the stock from $47 to $50.</li>
<li>Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) rose 9.4% to $20.92 as the company issued update on strategic and operational initiatives.</li>
<li>Northern Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) gained 8.5% to $121.44 following a report suggesting the Bank of New York Mellon approached the company to discuss a potential merger.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 8% to $7.83 as the company said Côté Gold Mine reached major milestone as processing plant operated at nameplate capacity of 36,000 tpd on average over thirty consecutive days.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) climbed 5.8% to $18.38.</li>
<li>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) rose 4.7% to $442.01 following upbeat quarterly sales.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

AIRO

CRCL

EPSM

EXEL

MANU

NTRS

OUST

SANA

SCHL

SPTN

TSLA

ZETA

Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $15 price target.

D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target

WIIM

CorMedix shares are trading higher after the company raised its Q2 net sales guidance.

CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agreement with the LDO customer to reflect the anticipated increased use of product. CorMedix expects a modest revenue contribution in June, with growth expected over the back half of 2025.
As a result of this new customer implementation and other positive business developments, CorMedix is increasing its second quarter net sales guidance from the previously communicated $31mm to a range of $35mm to $40mm.
"I am excited to announce that our LDO customer is moving forward with the implementation of DefenCath. Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections," says CorMedix CEO, Joseph Todisco. "CorMedix remains committed to our goal of ensuring broad access to this important infection reduction mechanism."

Biotech

Guidance

General

CorMedix Announces It Is Updating Its Q2 Net Sales Guidance From $31M To A Range Of $35M To $40M

RBC Capital analyst Leonid Timashev reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Outperform and raises the price target from $13 to $17.

Reiteration

RBC Capital Reiterates Outperform on Cormedix, Raises Price Target to $17

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and raises the price target from $12 to $15.

Needham Maintains Buy on Cormedix, Raises Price Target to $15

CorMedix shares are trading higher after the company reported better-than-expected Q1 financial results.

<ul>
<li>CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million, based on latest order trends and inventory tracking with current purchasing customers.</li>
</ul>

Cormedix Expects To Be At High-End Of Previously Announced 1H Net Sales Guidance Of $62M-$70M

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.24 by 25 percent. This is a 220 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $39.08 million which beat the analyst consensus estimate of $36.00 million by 8.55 percent.

Earnings

Earnings Beats

Cormedix Q1 EPS $0.30 Beats $0.24 Estimate, Sales $39.08M Beat $36.00M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Cormedix to report an earnings per share (EPS) of $0.23.
The announcement from Cormedix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 2.45% drop in the share price on the subsequent day.
Here's a look at Cormedix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.14</td>
<td>-0.10</td>
<td>-0.25</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.22</td>
<td>-0.05</td>
<td>-0.25</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746468176_0.png" alt="eps graph" />
<h3>Performance of Cormedix Shares</h3>
Shares of Cormedix were trading at $9.38 as of May 02. Over the last 52-week period, shares are up 53.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRMD/earnings">To track all earnings releases for Cormedix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Cormedix

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $12 price target.

Needham Reiterates Buy on Cormedix, Maintains $12 Price Target

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

AAOI

AAPL

ALHC

CVNA

GRAB

MRVL

NVDA

PCRX

RYTM

SHOP

SNDK

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

CorMedix shares are trading higher after the company issued Q1 preliminary revenue guidance above estimates.

<ul>
<li>Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new information, CorMedix is increasing its H1 2025 guidance for Net Sales to existing purchasing customers to a revised range of $62 million to $70 million.</li>
<li>While the Company is currently forecasting net sales from existing purchasing customers in 2Q 2025 to be lower than 1Q 2025, this is due to the timing of shipments to those customers between quarters, and does not suggest an anticipated decrease in patient utilization in the second quarter or the second half of 2025. CorMedix currently forecasts patient utilization with existing purchasing customers to continue to grow throughout 2025 as implementation expands to new patients, and currently anticipates unit shipments in H2 2025 to exceed shipments in H1 2025.</li>
<li>CorMedix expects patient enrollment for our Phase 3 study of DefenCath in patients receiving Total Parenteral Nutrition, or TPN, to begin in late April. The Company believes DefenCath, if approved for this indication, can achieve peak annual sales in this patient population of $150 million to $200 million, with a total addressable market opportunity of $500 million to $750 million.</li>
<li>Cash and short-term investments, excluding restricted cash, at March 31, 2025 amounted to approximately $77.5 million</li>
</ul>

Health Care

CorMedix Announces Preliminary Revenue Of $39M For 1Q 2025 Vs. Consensus Of $32.20M, And Expects 1Q 2025 Adjusted EBITDA (To Exceed $22.5M Once Final Numbers Are Reported)

Legal

Press Releases

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Comments

Cormedix

空売り

Cormedix (NASDAQ:CRMD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル